8:30 AM ET
8-K
M&A Deal
Horizon Space Acquisition I Signs $2B M&A Deal with ArcheNova Biotech Corp.
Horizon Space Acquisition I Corp. (HSPO), a SPAC, has entered into a definitive business combination agreement with clinical-stage biopharmaceutical company ArcheNova Biotech Corp. The transaction values ArcheNova at an implied enterprise value of $2.0 billion. Upon closing, the combined entity, ArcheNova Technology Co., Ltd, is expected to list on the Nasdaq Stock Market.
- Value
- $2B
- Counterparty
- ArcheNova Biotech Corp.